Dasatinib (Sprycel): A Tyrosine Kinase Inhibitor | Community Health

Dasatinib, marketed as Sprycel, is a potent tyrosine kinase inhibitor used to treat certain types of leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Developed by Bristol-Myers Squibb, dasatinib was first approved by the FDA in 2006. It works by inhibiting the activity of specific tyrosine kinases, including BCR-ABL, c-KIT, and the SRC family of kinases. With a Vibe score of 8, dasatinib has been a significant player in the treatment of CML, with a reported 90% overall survival rate at 5 years. However, its use has been associated with side effects such as myelosuppression, fluid retention, and gastrointestinal toxicity. As research continues to evolve, dasatinib remains a crucial component in the management of CML and ALL, with ongoing studies exploring its potential in combination with other therapies.